Xorphanol is a mixed [[agonist–antagonist]] of [[opioid receptor]]s,<ref name="ColbernGispen1988">{{cite book|author1=Deborah L. Colbern|author2=Willem Hendrik Gispen|author3=New York Academy of Sciences|title=Neural Mechanisms and Biological Significance of Grooming Behavior|url=https://books.google.com/books?id=EVEeAQAAIAAJ|date=1 January 1988|publisher=New York Academy of Sciences|isbn=978-0-89766-441-7}}</ref><ref name="GmerekCowan1988">{{cite journal|last1=Gmerek|first1=Debra E.|last2=Cowan|first2=A.|title=Role of Opioid Receptors in Bombesin-induced Grooming|journal=Annals of the New York Academy of Sciences|volume=525|issue=1 Neural Mechan|year=1988|pages=291–300|issn=0077-8923|doi=10.1111/j.1749-6632.1988.tb38614.x}}</ref><ref name="pmid3018570">{{cite journal | vauthors = Cowan A, Zhu XZ, Mosberg HI, Porreca F | title = Central infusion of rats with agents selective for different types of opioid receptor | journal = NIDA Res. Monogr. | volume = 67 | issue = | pages = 132–7 | year = 1986 | pmid = 3018570 | doi = | url = }}</ref> acting preferentially as a high-[[intrinsic activity|efficacy]] [[partial agonist]]/near-[[full agonist]] of the [[κ-opioid receptor]] (K<sub>i</sub> = 0.4&nbsp;nM; [[EC50|EC<sub>50</sub>]] = 3.3&nbsp;nM; {{abbr|I<sub>max</sub>|maximum inhibition}} = 49%; {{abbr|IA|relative intrinsic activity}} = 0.84)<ref name="GharagozlouHashemi2006">{{cite journal|last1=Gharagozlou|first1=Parham|last2=Hashemi|first2=Ezzat|last3=DeLorey|first3=TimothyM|last4=Clark|first4=J David|last5=Lameh|first5=Jelveh|title=Pharmacological profiles of opioid ligands at Kappa opioid receptors|journal=BMC Pharmacology|volume=6|issue=1|year=2006|pages=3|issn=1471-2210|doi=10.1186/1471-2210-6-3|pmid=16433932|pmc=1403760}}</ref><ref name="Testa2013">{{cite book|author=Bernard Testa|title=Advances in Drug Research|url=https://books.google.com/books?id=eiAlBQAAQBAJ&pg=PA245|date=22 October 2013|publisher=Elsevier|isbn=978-1-4832-8798-0|pages=245–}}</ref><ref name="pmid12513698">{{cite journal | vauthors = Gharagozlou P, Demirci H, David Clark J, Lameh J | title = Activity of opioid ligands in cells expressing cloned mu opioid receptors | journal = BMC Pharmacol. | volume = 3 | issue = | pages = 1 | year = 2003 | pmid = 12513698 | pmc = 140036 | doi = 10.1186/1471-2210-3-1 | url = }}</ref> and to a lesser extent as a [[partial agonist]] of the [[μ-opioid receptor]] (K<sub>i</sub> = 0.25&nbsp;nM; [[IC50|IC<sub>50</sub>]] = 3.4&nbsp;nM; {{abbr|I<sub>max</sub>|maximum inhibition}} = 29%) with lower relative [[intrinsic activity]] and marked [[receptor antagonist|antagonistic]] potential (including the ability to antagonize [[morphine]]-induced effects and induce [[opioid withdrawal]] in [[opioid dependence|opioid-dependent]] individuals).<ref name="Lednicer1990" /><ref name="Kadam2007">{{cite book|author=Dr. S. S. Kadam|title=PRINCIPLES OF MEDICINAL CHEMISTRY Vol. - II|url=https://books.google.com/books?id=Z7Pb3lJuRksC&pg=PA214|date=1 July 2007|publisher=Pragati Books Pvt. Ltd.|isbn=978-81-85790-03-9|pages=214–}}</ref> The drug has also been found to act as an agonist of the [[δ-opioid receptor]] (K<sub>i</sub> = 1.0&nbsp;nM; IC<sub>50</sub> = 8&nbsp;nM; {{abbr|I<sub>max</sub>|maximum inhibition}} = 76%).<ref name="GharagozlouDemirci2002">{{cite journal|last1=Gharagozlou|first1=Parham|last2=Demirci|first2=Hasan|last3=Clark|first3=J|last4=Lameh|first4=Jelveh|journal=BMC Neuroscience|volume=3|issue=1|year=2002|pages=19|issn=1471-2202|doi=10.1186/1471-2202-3-19}}</ref>

 
Xorphanol produces potent analgesia, and was originally claimed to possess a minimal potential for [[drug dependence|dependence]] or [[drug abuse|abuse]].<ref>{{cite journal | last1 = Polazzi | first1 = JO | last2 = Kotick | first2 = MP | last3 = Howes | first3 = JF | last4 = Bousquet | first4 = AR | title = Analgesic narcotic antagonists. 9. 6-Methylene-8 beta-alkyl-N-(cycloalkylmethyl)-3-hydroxy- or -methoxymorphinans | journal = Journal of Medicinal Chemistry | volume = 24 | issue = 12 | pages = 1516–8 | year = 1981 | pmid = 6796691 | doi=10.1021/jm00144a029}}</ref><ref>{{cite journal | last1 = McCarthy | first1 = PS | last2 = Howlett | first2 = GJ | title = Physical dependence induced by opiate partial agonists in the rat | journal = Neuropeptides | volume = 5 | issue = 1–3 | pages = 11–4 | year = 1984 | pmid = 6152317 | doi=10.1016/0143-4179(84)90014-3}}</ref><ref>{{cite journal | last1 = Howes | first1 = JF | last2 = Villarreal | first2 = JE | last3 = Harris | first3 = LS | last4 = Essigmann | first4 = EM | last5 = Cowan | first5 = A | title = Xorphanol | journal = Drug and Alcohol Dependence | volume = 14 | issue = 3–4 | pages = 373–80 | year = 1985 | pmid = 4039650 | doi=10.1016/0376-8716(85)90068-7}}</ref> Moreover, [[side effect]]s in [[animal study|animal studies]] were relatively mild, with only [[sedation]] and [[nausea]] being prominent, although it also produced [[convulsions]] at the highest dose tested.<ref>{{cite journal | last1 = Porter | first1 = MC | last2 = Hartnagel | first2 = RE | last3 = Clemens | first3 = GR | last4 = Kowalski | first4 = RL | last5 = Bare | first5 = JJ | last6 = Halliwell | first6 = WE | last7 = Kitchen | first7 = DN | title = Preclinical toxicity and teratogenicity studies with the narcotic antagonist analgesic drug TR5379M | journal = Fundamental and Applied Toxicology | volume = 3 | issue = 5 | pages = 478–82 | year = 1983 | pmid = 6642105 | doi = 10.1016/S0272-0590(83)80023-2 }}</ref> However, human trials revealed additional side effects such as [[headache]]s and [[euphoria (emotion)|euphoria]], and this was the subject of a lawsuit between the drug's inventors and the company to which they had licensed the marketing rights, which claimed that these side effects had not been revealed to them during the license negotiations.<ref>[http://bulk.resource.org/courts.gov/c/F3/13/13.F3d.6.93-1385.html ''Maruho Company Ltd v Miles Inc'' (1993) 13 F.3d 6]</ref> As a result of this dispute, the drug was never marketed commercially.
